Jefferies has maintained its Underperform rating on Alkem Laboratories with a target price of ₹4,950, suggesting an 11.1% downside from the current market price (CMP) of ₹5,565.15. The company’s Q2 results fell below Jefferies’ estimates due to lower revenue growth across regions. Alkem has adjusted its revenue growth guidance downward, while raising its margin target. Expectations for growth in India have been moderated, though the U.S. business is anticipated to gain traction starting from Q2, and the Rest of World (RoW) outlook remains strong.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor before making any investment decisions.
